Safety and PK of Poseltinib in Healthy Japanese and Caucasian Subjects

Phase 1, randomised, double-blind trial of poseltinib in rheumatoid arthritis (RA) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration up to 31 Days. Started Mar 2017; status: completed.